EP0637960A1 - INDOLIZINO 1,2-b]QUINOLINONES SUBSTITUEES - Google Patents

INDOLIZINO 1,2-b]QUINOLINONES SUBSTITUEES

Info

Publication number
EP0637960A1
EP0637960A1 EP93912281A EP93912281A EP0637960A1 EP 0637960 A1 EP0637960 A1 EP 0637960A1 EP 93912281 A EP93912281 A EP 93912281A EP 93912281 A EP93912281 A EP 93912281A EP 0637960 A1 EP0637960 A1 EP 0637960A1
Authority
EP
European Patent Office
Prior art keywords
compound
oxy
quinolin
propyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93912281A
Other languages
German (de)
English (en)
Other versions
EP0637960A4 (fr
Inventor
David Alan Berges
Robert Philip Hertzberg
Randall Keith Johnson
William Dennis Kingsbury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority claimed from PCT/US1993/003596 external-priority patent/WO1993020818A1/fr
Publication of EP0637960A1 publication Critical patent/EP0637960A1/fr
Publication of EP0637960A4 publication Critical patent/EP0637960A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00

Definitions

  • This invention relates to methods of treating viral infections, antiviral compounds, and pharmaceutical compositions thereof. More specifically, this invention relates to a method of treating viral infections, certain indolizino[l,2-b]quinolinyl derivatives which have antiviral activity and pharmaceutical compositions thereof.
  • Camptothecin is an example of such compounds. It is a water-insoluble, cytotoxic alkaloid produced by Camptotheca acuminata trees indigenous to China and Nothapodytes foetida trees indigenous to India. Camptothecin and its close congeners are known to inhibit eukaryotic topoisomerase I. In fact, the cytotoxic and antitumor activity of camptothecin and its close congeners results from inhibition of eukaryotic topoisomerase I ⁇ Cancer Res. 1988, 48, 1722; Molec. Pharmacol.
  • camptothecin possesses antiviral activity.
  • camptothecin and its close analogs that have a hydroxylactone moiety cannot be considered as useful in vivo antiviral agents because they undesirably inhibit mammalian topoisomerase I, as well as host cell DNA replication, and are cytotoxic to mammalian cells.
  • camptothecin is not an attractive candidate for drug development as an antiviral agent because of unacceptable dose-limiting toxicity, unpredictable toxicity, and poor aqueous solubility, and/or unacceptable shelf life stability.
  • One aspect of the present invention provides a method for treating viral infections comprising administering to an infected host in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, alone or in combination with a carrier
  • V is -OH, -OCOR 14 OP(O)(OH)R 15 or -NRR 1 ;
  • R ⁇ is -H or -OR
  • R 2 is -H or lower alkyl
  • R 1 ⁇ is lower alkyl
  • R and R are independently selected from the group consisting of -H, -Ci-6 alkyl, and, when R and R are substituted on nitrogen, R and R can be taken together to form a 5-7 membered saturated heterocyclic ring containing the nitrogen;
  • R ⁇ is -CR ⁇ Ri ⁇ RH.
  • R 15 is OH, OR 18 or CH 2 NH2;
  • R ⁇ 6 is H or the side chain of any naturally occuring a-amino acid
  • X is any pharmaceutically acceptable anion
  • R 8 is lower alkyl
  • X is -CH(OH)CH(OH)CH3, -CHR3R 4 or R .
  • R 2 is -H, -C(O)H, -COR 14 - or -P(O)(OH)R 15 ;
  • R 3 is -OH, -OCOR 14 , or -OP(O)(OH)R 1 5
  • R 4 is -H, lower alkyl, or -OR
  • R6 is -H or lower alkyl.
  • R 7 , R , R 10 or R 11 if one of R 7 , R , R 10 or R 11 is other than -H, only one of the others may be other than -H; b) only one of R 7 , R 9 , R 10 or R 1 1 may be -NRR 1 ; c) when X is -CHR 3 R 4 and R 4 is -OR, R 3 is -OH;
  • This invention also provides compounds having the formula of Formula I as described hereinabove, except that:
  • compositions comprising a compound of Formula I in combination with a pharmaceutically acceptable carrier or excipient.
  • present invention relates to processes for making a compound of Formula I.
  • Aliphatic is intended to include saturated and unsaturated radicals. This includes normal and branched chains, saturated or mono or poly unsaturated chains where both double and triple bonds may be present in any combination.
  • the phrase "lower alkyl” and “Cj.g alkyl” refer to an alkyl group of 1 to 6 carbon atoms in any isomeric form, but particularly the normal or linear form.
  • Lower alkoxy means the group lower alkyl-O-.
  • Halo means fluoro, chloro, bromo or iodo.
  • Acyl means the radical having a terminal carbonyl carbon.
  • 5-7 membered saturated heterocyclic ring containing the nitrogen is intended to include saturated rings such as piperidine, pyrrolidine, morpholine, piperazine, and N-alkyl piperazine.
  • saturated rings such as piperidine, pyrrolidine, morpholine, piperazine, and N-alkyl piperazine.
  • l,4'-bipiperidine-r-carboxy is used to identify the following radical:
  • Salts of any sort may be made from these compounds, provided that an acidic group or a sufficiently basic nitrogen is present in the compound.
  • Particularly preferred are the pharmaceutically acceptable salts of the instant compounds. These salts are defined as those which are acceptable in their application to a pharmaceutical use, meaning that the salt will retain the biological activity of the parent compound and that the salt will not have untoward or deleterious effects in its application and use in treating diseases.
  • compositions are prepared in a standard manner.
  • the parent compound in a suitable solvent, is reacted with an excess of an organic or inorganic acid in the case of acid addition salts of a base moiety; or an excess of organic or inorganic base in the case where the parent contains an acid group.
  • Representative acids are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, maleic acid, succinic acid and methanesulfonic acid.
  • Cationic salts are readily prepared from alkali metals such as sodium, potassium, calcium, magnesium, zinc, copper or the like as well as ammonia.
  • Organic bases include the mono or disubstituted amines, ethylenediamine, piperazine, amino acids, caffeine, and the like.
  • the present invention provides a method of treating viral infections comprising administering to an infected host in need thereof an effective amount of a compound of Formula I as described hereinabove, or a pharmaceutically acceptable salt thereof, alone or in combination with a carrier or excipient.
  • the present method is useful for treating viral infections in animals, particularly mammals, most particularly humans, caused by a broad variety of DNA replicating animal viruses.
  • the present method is particularly useful in treating viral infections caused by herpes simplex virus, particularly herpes simplex virus type 1 (HSN1) and herpes simplex virus type 2 (HSV2), varicella zoster virus (VZV), or cytomegalovirus (CMV) when the infected host is a mammal, particularly when the infected host is human.
  • HSN1 herpes simplex virus type 1
  • HSV2 herpes simplex virus type 2
  • VZV varicella zoster virus
  • CMV cytomegalovirus
  • a preferred method of treating viral infections according to the present invention uses compounds of Formula IMl
  • X is -CH(OH)CH(OH)CH3, -CHR R 4 , or and Y is -CH3 or -CH2OR 2
  • Formula IMl corresponding to Formula I wherein R 7 , R 9 , R 1 ⁇ , and R 1 are each - H and X and Y are as described herein.
  • a more preferred method uses compounds of Formula IMl where X is CHR 3 R 4 where R 3 is -OH, OCOR 14 or
  • OP(O)(OH)R 15 and Y is -CH3, where X is where R 6 is -H or lower alkyl and Y is -CH3 or -CH2OR 2 , or where X is -CH(OH)CH(OH)CH3 and Y is -CH3.
  • Another preferred method for treating viral infections according to the present invention uses compounds of Formula IM2
  • Formula IM2 corresponding to Formula I wherein R 7 , R 9 , and R 1 are each H, R ⁇ is as defined hereinabove for Formula I except that R 1 ⁇ is not -H, and X and Y are as defined hereinabove in Formula I.
  • a more preferred method uses compounds of Formula IM2 where R ⁇ ° is -OR, -CN, COR 12 , or -(CH2) n CH2V; or X is -CHR 3 R 4 where R 3 is -OH, OCOR 14 or OP(O)(OH)R 15 and R 4 is -H or lower alkyl and Y is
  • X is R where R 6 is -H or lower alkyl and Y is -CH3 or CH2OR 2
  • Formula IM3 corresponding to Formula I wherein R 7 and R 1 are each -H, R 9 and R ⁇ are as defined hereinabove for Formula I except that R 9 and R ⁇ are each not -H, and X and Y are as defined hereinabove in Formula L
  • a more preferred method uses compounds of Formula IM3 wherein R 9 is -(CH2)nCH2V, R 10 is -OR, X is CHR3R 4 where R 3 is -OH, OCOR 14 or OP(O)(OH)R 1 5 and R 4 is -H or lower alkyl, or X is is -H or lower alkyl, and Y is -CH3 or
  • Another preferred method of use according to the present invention uses compounds of Formula IM4
  • Formula IM4 corresponding to Formula I wherein R 9 , R 1 ⁇ and R 11 are each -H, R 7 is as defined hereinabove except that R 7 is not -H, and X and Y are as defined hereinabove in Formula I.
  • a more preferred method uses compounds of Formula IM4 where R 7 is lower alkyl, -CN, or -(CH2) n CH2V; X is CHR R4 where R 3 is -
  • OH, OCOR 14 or OP(O)(OH)R 1 5 and R 4 is -H or lower alkyl, or X is where R 6 is -H or lower alkyl, and Y is -CH3 or CH2OR 2 .
  • Yet another preferred method of use according to the present invention uses compounds of Formula IM5
  • Formula IM5 corresponding to Formula I wherein R 7 , R 1 ⁇ and R 1 are -H, R 9 is as defined hereinabove for Formula I except that R 9 is not -H, and X and Y are as defined hereinabove in Formula I.
  • a more preferred method uses compounds of Formula IM5 where R 9 is -OR, X is CHR 3 R 4 where R is -OH,
  • OCOR 14 or OP(O)(OH)R 15 and R 4 is -H or lower alkyl, or X is R where R 6 is -H or lower alkyl, and Y is -CH3 or CH 2 OR 2
  • Still another preferred method of use according to the present invention uses compounds is represented by Formula 1M6
  • Formula IM6 corresponding to Formula I wherein R 7 , R 9 and R ⁇ are each H, R * ⁇ is -OR, and X and Y are as defined hereinabove in Formula I.
  • a more preferred method uses compounds of Formula IM6 where R 11 is OR, X is CHR3R 4 where R
  • R 4 is -OH, OCOR 14 or OP(O)(OH)R 15 and R 4 is -H_or lower alkyl, or X is where R 6 is -H or lower alkyl, and Y is -CH3 or CH2OR 2 .
  • the present invention also provides compounds having antiviral activity, and pharmaceutically acceptable salts thereof, said compound having the structure represented by Formula I hereinabove except that: a) hen R7, R9, RlO f and R 11 are all -H and Y is -CH3, then X _s not
  • R 6 is not -CH 2 CH when Y is -CH3) or X is CHR 3 R 4 where R is -OH, OCOR 14 or OP(O)(OH)R 15 and R 4 is -H or lower alkyl (provided that R 4 is not -CH2CH3 when R is OH), and Y is -CH3.
  • Formula IN2 corresponding to Formula I wherein R 7 , R 9 and R 11 are each -H, R 1 ⁇ is as described hereinabove for Formula I except that R 1 ⁇ is not -H, and X and Y are as defined hereinabove for Formula I. More preferred compounds of Formula IN2 include those where R 10 is -OR, -CN, -COR 12 , or -(CH2) n CH2V, and X is CHR3R 4 where R3 is -OH, OCOR 14 or OP(O)(OH)R J 5 and R 4 is -H or lower
  • Formula IN3 corresponding to Formula I wherein R 7 and R 1 are each -H, R 9 and iO are as described hereinabove for Formula I except that R 9 and R ⁇ are not -H, and X and Y are as defined hereinabove for Formula I. More preferred compounds of Formula IN3 include those where R 9 is -(CH2) n CH2V, R 10 is -OR, X is CHR 3 R 4 where R 3 is -OH, OCOR 14 or OP(O)(OH)R 15 and R 4 is -H or lower
  • Formula IN4 corresponding to Formula I wherein R 9 , R 1 ⁇ and R 1 are each -H, R 7 is as described hereinabove for Formula I except that R 7 is not -H, and X and Y are as defined hereinabove for Formula L
  • More preferred compounds of Formula IN4 include those compounds where R 7 is lower alkyl, -CN, or -(CH2)nCH2V; X is CHR3R 4 where R 3 is -OH, OCOR 14 or OP(O)(OH)R 15 and R 4 is -H or lower
  • Formula IN5 corresponding to Formula I wherein R 7 , R!0 and R 11 are each -H, R 9 is as described hereinabove for Formula I except that R 9 is not -H, and X and Y are as defined hereinabove for Formula I. More preferred compounds of Formula IN5 include those compounds where R 9 is -OR, X is CHR3R 4 where R3 is -OH,
  • OCOR 14 or OP(O)(OH)R 15 and R 4 is -H or lower alkyl, or X is where R 6 is -H or lower alkyl, and Y is -CH3 or CH2OR 2 .
  • Formula IN6 corresponding to Formula I wherein R 7 , R 9 and R 1 ⁇ are each -H, R 11 is -OR, and X and Y are as defined hereinabove for Formula I. More preferred compounds of Formula IN6 are compounds where R 11 is -OR, X is CHR R 4 where R3 is -OH, OCOR 14 or OP(O)(OH)R 1 5 and R 4 is -H or lower alkyl, or X is
  • R 6 is -H or lower alkyl, and Y is -CH3 or CH2OR 2 .
  • Y is -CH3 or CH2OR 2 .
  • the inventive compounds are prepared by opening the lactone ring of camptothecin or a camptothecin derivative which may have the desired R 7 - R 11 substituent to obtain an 8-me_hyl-7-(l-oxopropyl)indolizino[l,2-b]quinolin- 9(1 lH)-one.
  • the lactone ring may be opened and then the R 7 - R 11 substituents introduced.
  • an existing R 7 - R 11 group is modified to obtain the desired compound.
  • the resulting X and Y groups may be further modified as needed to make the subject compounds.
  • Starting materials are commercially available or can be made by published methods.
  • Camptothecin, lO-hydroxycamptothecin and 9-hydroxycamptothecin are natural products. Camptothecin and 10-hydroxycamptothecin are available from sources in the People's Republic of China.
  • a 9-hydroxycamptothecin compound which can be used as starting material for making some of the inventive compounds is described in Published Japanese Patent Application No.59-51,289.
  • the syntheses of 9- and 12-nitrocamptothecins are described by Wall, et al. (J. Med. Chem. 1986, 29, 2358).
  • a total synthesis of camptothecin is described by Wall, et al., J. Med. Chem. 1980, 23, 554.
  • the 1980 Wall, et al. synthesis can be used as a means to introduce one or more R 7 - R 11 substituents into the compounds of Formula I. This involves modifying the Wall synthesis at the appropriate step in a manner which puts in place the desired substituent, then continuing with the described synthesis.
  • Compounds of formula 1 are converted to compounds of formula 2 by heating the compounds in a high boiling, preferably unreactive, solvent such as N,N-dimethylformamide or triglyme (triethylene glycol dimethyl ether).
  • a high boiling, preferably unreactive, solvent such as N,N-dimethylformamide or triglyme (triethylene glycol dimethyl ether).
  • the keto group of compounds of formula 2 can be reduced to give the corresponding hydroxy compounds 3 from which the halo compounds 4 can be derived.
  • the keto group also can be converted to an oxime (compounds 5) which can in turn be reduced to give the primary amino compounds 6.
  • the keto group also can be converted to a ketal group such as a 1,3-dioxolane (compounds 7, which are useful intermediates for further transformations).
  • the hydroxyl group of compounds 3 can also be acylated to produce esters, carbonates, and carbamates (8) or phosphorylated to produce phosphates and phosphonates (9) wherein R 2 ⁇ and R 21 are groups convertible into R 14 and R 1 ⁇ respectively, by either deprotection or further elaboration by well-known methods.
  • Some ring substituents may be labile to the conditions used in the preferred method of making compounds 2 as given in Scheme 1.
  • the sequence set out in Scheme 5 can provide access to certain of those compounds or provide intermediates for making other compounds.
  • the compounds in Scheme 6 are prepared either by alkylation (compounds 21) or acylation (compounds 22, 23, and 24) of the 2-hydroxy ketones 20 or by replacement of the 2-hydroxy group in the ketals (19) via the triflates (25). Cyanation of the triflates following the method of Kosugi, M, et al, Chem..Lett. 1981, 69 gives compounds 26 which are hydrolyzed to compounds 27. Catalytic hydrogenation of the cyano group of compounds 26 gives aminomethyl ketals 28 which upon hydrolysis gives the ketones 29.
  • a carbonyl group can be introduced onto the ring, for example by the procedure of Cacchi, S, et al, TetrahedronLett. 1986, 27, 3931. If an amine or alcohol is used, the corresponding amides (30) or esters (32) are obtained which are then hydrolyzed to the respective keto compounds 31 and 33. Reduction of the esters 32 with a hydride gives the primary alcohols 34 which upon hydrolysis produce the keto alcohols 35 which can be acylated to give carboxylates, carbonates and carbamates or phosphorylated to give phosphates or phosphonates by methods similar to those used for preparing such derivatives from compounds 3.
  • Aldehydes (compounds 36) can be made by oxidizing the alcohols 34 using a mild oxidant which gives the aldehyde in preference to the acid (for example, Mn ⁇ 2). Deprotection gives the keto aldehydes 37.
  • the triflates are converted to vinyl ethers 38 following the method of Cabri, W., et al. (J. Org. Chem. 1990, 55, 3654), and then compounds 38 are hydrolyzed to diketones 39.
  • Selective hydrolysis of the enol ether function in compounds 38 produces the 2-keto compounds that can be reduced to secondary alcohols from which the ketal groups can be removed and the alcohol function acylated or phosphorylated as described for compounds 3.
  • amines can be alkylated (42), sulfonylated (44), or acylated (46) by known means and then deprotected to compounds 43, 45, and 47, respectively.
  • Halogenation of compounds 19 is accomplished by standard means to produce 1-halo ketals 48 which are cleaved to the corresponding ketones 49.
  • Cyano ketals 50 are prepared using the iodides (48) in the cyanation reaction described for the synthesis of compounds 26. Cleavage of compounds 50 gives compounds 51, or alternatively, the hydroxy function can be removed from 50 by converting the compounds to the corresponding triflates 52 and then reducing them to compounds 53 by the method of Cacchi, S. et al., Tetrahedron Lett. 1986, 27, 5541. Hydrolysis of ketals 53 gives ketones 54.
  • the hydroxy compounds 57 are made as described by Sugasawa, T., et al.,
  • the triflates (58) are prepared in the usual manner. Reduction to compounds 59 is carried out by the same method used for compounds 52. Cyanation of the triflates to give compounds 60 uses the method — ⁇ employed to prepare compounds 26. Alkoxyvinylation of the triflates to give compounds 61 is carried out as in the preparation of compounds 38; acid hydrolysis of the vinyl ethers gives the ketones 62 which upon reaction with diazomethane by the method of Kametani, T., et al. (Heterocycles 1975, 3, 167) give methyl derivatives 63 which are reduced by hydrides to the alcohols 64.
  • 12-Hydroxymethyl compounds 76 are prepared by the method of Miyaska, T. et al. (Heterocycles 1981, 16, 1713) using ferrous sulfate, hydrogen peroxide and methanol with sulfuric acid. These alcohols are acylated or phosphorylated as described for compounds 3 to produce carboxylates, carbonates and carbamates, or phosphates and phosphonates.
  • 12-alkyl compounds 77 are prepared by the method of Miyasaka, T. et al. (U.S. Pat. No. 4,399,282).
  • the chloro substituent of compounds 80 can be replaced with an iodo group (85) by heating with potassium iodide in acetic acid containing some acetic anhydride.
  • iodo derivatives are easily used in various coupling reactions similar to those carried out with triflates 25 and 58. Cyanation gives compounds 86 which are deblocked to ketones 87 or are reduced to aminornethyl compounds 88 which give ketones 89 upon hydrolysis. Likewise, propynylamines 90 can be produced and then deprotected to compounds 91 or catalytically hydrogenated to compounds 92 and 94 which are hydrolyzed to keto compounds 93 and 95, respectively. Heating compounds 85 with sodium acetate in acetic acid gives the 12-hydroxy compounds 96 which can be alkylated using either base and alkyl halides or diazoalkanes to give 12-alkoxy compounds 97 which upon deprotection afford ketones 98.
  • the 12-hydroxy methyl compounds 76 can be protected and then activated for displacement reactions by conversion to a sulfonate (99), for example, a mesylate. Cyanide displacement on compounds 99 gives the ketals 100 which upon hydrolysis give 12-cyanomethyl ketones 101. The cyano ketals can also be reduced to aminoethyl compounds 102 that give ketones 103 after hydrolysis. Treatment of sulfonates 99 with alcohols in the presence of bases gives ethers 104 which can be converted to keto ethers 105.
  • a sulfonate 99
  • mesylate for example, a mesylate
  • the compounds of the present invention exhibit antiviral activity and are generally useful in treating DNA replicating animal virus infections, particularly those caused by viruses in the herpes family. More specifically, these compounds are useful in treating infections caused by the following human pathogens:
  • Herpes Simplex virus types 1 and 2 Cytomegalovirus; Varicella Zoster virus; Epstein Barr virus; and Papilloma virus (multiple types).
  • Lifections caused by the following animal pathogens may also be treated with the present compounds: Equine Herpes virus; Porcine Herpes virus; Marek's disease virus; Feline Rhinotracheitis virus; and Bovine Herpes virus.
  • the assay used to test the compounds of the present invention for antiviral activity was taken from the literature and was modified in well-known ways to adapt it to currently available technology. A generalized description of the assay follows.
  • EMEM Eagle's Minimum Essential Medium
  • FBS fetal bovine serum
  • HBSS Hank's buffered saline solution
  • This procedure can be used to test compound efficacy against many viruses besides herpes simplex by simply modifying the cell type used in the first step to match the virus being tested and following the procedure outlined above.
  • Other cell types which could be used in this assay include mouse mammary tumor cells, human lung fibroblasts, sheep chorioplexus cells, and green monkey kidney cells.
  • Other assays which are useful for determining the antiviral activity of the present compounds include the following types: cell count, clonogenic, cytopathic effect, dish-colony formation, microtiter-growth inhibition, thymidine incorporation and yield reduction. Each of these well-known assays is in the literature and selected assays are available commercially.
  • compositions prepared from compounds of the present invention.
  • Such compositions have utility for human and veterinary antiviral use, and for treating viral infections in plants, e.g., agricultural or ornamental seeds and plants.
  • Such compositions comprise a carrier which is acceptable for the intended end use together with at least one inventive compound.
  • the carrier may be a liquid, or spray, or may be formulated in a solid, non-degradeable or degradeable form for insertion in the rumen.
  • the compound can be mixed with a fertilizer, other microbiocides such as fungicides, or insecticides and the like.
  • the present compounds may also be formulated in powders or sprays for application to plant surfaces.
  • compositions of this invention comprise one or more . compounds of the present invention in admixture with an inert pharmaceutically acceptable carrier or diluent.
  • Compositions may contain an effective amount of the inventive compound in one unit, such as in a single pill, capsule, or pre-measured intravenous dose or pre-filled syringe for injection, or, as is frequently the case, the composition may be prepared in individual dose forms where one unit, such as a pill, contains a sub-optimal dose with the user being instructed to take two or more unit doses per treatment.
  • the composition When the composition is presented as a cream, it contains a discrete amount of drug and the user applies an effective amount of the cream one or more times until the disease is in remission or has been effectively treated. Concentrates for later dilution by th& end user may also be prepared, for instance for IV formulations and multi-dose injectable formulations.
  • Carriers or diluents contemplated for use in these compositions are generally known in the pharmaceutical formulary arts. Reference to useful materials can be found in well known compilations such as Remington's Pharmaceutical Sciences. Mack Publishing Co., Easton, PA, 18042, USA.
  • compositions and the pharmaceutically acceptable carrier or diluent will, of course, depend upon the intended route of administration, for example, by intravenous and intramuscular injection, parenterally, topically, orally, or by inhalation.
  • the pharmaceutical composition may be in the form of a sterile injectable liquid such as an ampule or an aqueous or nonaqueous liquid suspension.
  • a sterile injectable liquid such as an ampule or an aqueous or nonaqueous liquid suspension.
  • the pharmaceutical composition may be in the form of a cream, ointment, liniment, lotion, paste, spray or drops suitable for administration to the skin, eye, ear, nose or genitalia.
  • the pharmaceutical composition may be in the form of a tablet, capsule, powder, pellet, atroche, lozenge, syrup, liquid, or emulsion.
  • the pharmaceutically acceptable carrier employed may be either a solid or liquid. Exemplary of solid carriers are lactose, kaolin, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, mannitol, stearic acid and the like.
  • liquid carriers or diluents examples include: for aqueous systems, water; for non-aqueous systems, ethanol, glycerin, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, liquid paraffins and mixtures thereof with water.
  • pharmaceutically acceptable carriers include dichlorodifluoromethane, chlorotrifluoroethane and compressed carbon dioxide.
  • the instant compositions may include other ingredients such as stabilizers, antioxidants, preservatives, lubricants, suspending agents, viscosity modifiers and the like, provided that the additional ingredients do not have a detrimental effect on the therapeutic action of the instant compositions.
  • the carrier or diluent may include time delay materials well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like.
  • a pharmaceutically acceptable salt of a compound of the present invention is dissolved in an aqueous solution of an organic or inorganic acid or base.
  • the inventive compound may be dissolved in a suitable co-solvent or combinations thereof.
  • suitable cosolvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in concentrations ranging from 0-60% of the total volume.
  • the actual preferred dosages of the compounds of the present invention used in the pharmaceutical and other compositions of this invention will vary according to the particular complex being used, the particular composition formulated, the mode of administration and the particular site, host and disease being treated.
  • These compounds are active in the concentration ranges of two commercial antiviral drugs, Cytovene (ganciclovir) and Zovirax (acyclovir).
  • Cytovene ganciclovir
  • Zovirax acyclovir
  • the latter is manufactured in 200 mg capsules with instructions for treating herpes simplex viruses by taking one capsule every 4 hours, but not to exceed 5 capsules per day.
  • Example 2 ( ⁇ )-2-Cvano-7-(l-hydroxypropy -8-methylindolizinorL2-blquinolin-9(l lH -one
  • the title compound was prepared according to the procedure in Example 1 except using 2-cyano-8-methyl-7-(l-oxopropyl)indolizino[l,2-b]quinolin-9(l 1H)- one.
  • N-[(l,l-dimethylethoxy)carbonyl]-D-proline (6.74 g, 31.3 mmol) in C ⁇ 2CI2 (47 mL) under an argon atmosphere was added dicyclohexylcarbodiimide (3.22 g, 15.6 mmol). After stirring at room temperature for 2 h, the mixture was filtered and concentrated under reduced pressure to afford N-I(l,l-dimethylethoxy)carbonyl]-D-proline anhydride.
  • the title compound was prepared according to the procedure in Example 3 A except using N,l-bis[(l,l-dimethylethoxy)carbonyl]-L-histidine, N,N'- chisopropylcarbodiimide and ( ⁇ )-7-(l-hydroxypropyl)-8- methyl doH__ino[l,2-bJquinolin-9(llH)-one.
  • the tide compound was prepared according to the procedure in Example 3 A except using N-[(l,l-dimethylethoxy)carbonyl]-L-valine and ( ⁇ )-7-(l- hydroxypropyl)-8-methylindolizino[ 1 ,2-b]quinolin-9( 1 IHVone.
  • the tide compound was prepared according to the procedure in Example 3B except using ( ⁇ )-8-methyl-7-[l-[[2-[[(l,l-dimethylethoxy)carbonyl]amino]-3- methyl-l-oxobutyl]oxy]propyl]indolizino[l,2-b]quinolin-9(l IHVone.
  • the tide compound was prepared according to the procedure in Example 3B except using ( ⁇ )-8-methyl-7-[l-[[2-[[(l,l-dimethyIethoxy)carbonyl]amino]-2- methyl-l-oxopropyl]oxy]propyl]mdoUz_no[l,2-b]quinolin-9(llH)-one.
  • the tide compound was prepared according to the procedure in Example 3 A except using ( ⁇ )-12-cyano-7-(l-hydroxypropyl)-8-methylindolizino[l,2-b]quinolin-
  • the tide compound was prepared according to the procedure in Example 5E except using ( ⁇ )-7-[l-[(aminoacetyl)oxy]propyl]-8-methylindolizino [I,2-b]quinolin-9(llH)-one.
  • a stream of dimethylamine was introduced into a solution containing ( ⁇ )-7- [l-[(iodoacetyl)oxy]propyl]-8-methylindolizino[l,2-b]quinolin-9(l lH)-one (50 mg, 0.11 mmol). in anhydrous C ⁇ 2CI2 (15 mL). The resulting solution was allowed to stir for 2 h and then was concentrated under reduced pressure. The residue was partitioned between CH2CI2 and H2O, and the organic layer was washed several times with H2O and dried over sodium sulfate. Into this solution was bubbled a stream of HCI gas, and the resulting cloudy mixture was stirred for 15 min and then was concentrated in vacuo.
  • the tide compound was prepared according to the procedure in Example 13 except using ( ⁇ )-7-[l-[(iodoacetyl)oxy]propyl]-8-methylindolizino[l,2-b]quinolin- 9(llH)-one and morpholine.
  • the tide compound was prepared according to the procedure in Example 13 except using ( ⁇ )-7-[ l-[(iodoacetyl)oxy]propyl]-8-methylindolizino[l,2-b]quinolin- 9(llH)-one and N-methylpiperazine.
  • the tide compound was prepared according to the procedure in Example 13 except using ( ⁇ )-7-[l-[(iodoacetyl)oxy]propyl]-8-methylindolizino[l,2-b]quinolin- 9(llH)-one and imidazole.
  • the tide compound was prepared according to the procedure in Example 13 except using ( ⁇ )-7-[l-[(iodoacetyl)oxy]propyl]-8-methylindolizino[l,2-b]quinolin- 9(1 lH)-one and pyridine.
  • the organic layer was washed with H2O and dried over sodium sulfate.
  • the solvent was removed in vacuo, and the residue was purified by column chromatography eluting with a solvent gradient of 0-5% MeOH/CH2Cl2.
  • the isolated material was treated with 3 mL H2O and 0.3 mL 0.1 N HCI and lyophilized to afford the tide compound as a beige solid.
  • the tide compound was prepared according to the procedure in Example 21 except using ( ⁇ )-7-(l-hydroxypropyl)-8-methylindolizino[l,2-b]quinolin-9(l 1HV one and [[[(9-fluorenylmethoxy)carbonyl]amino]methyl]phosphonic acid.
  • the tide compound was prepared according to the procedure in Example 5E except using 12-0 ⁇ ydroxymethyl)-8-methyl-:7-(l-oxopropyl)indolizino[l,2- b]quinolin-9(llH)-one and N-[(l,l-dimethyIethoxy)carbonyl]glycine.
  • the tide compound was prepared according-to the procedure in Example 5B except using 8-methyl-12-[[[[[[[(l,l- dimemyIemoxy)carbonyl]amino]acetyl]oxy]methyl]-7-(l-oxopropyl)indolizino[l,2- b]quinolin-9(HH)-one.
  • i ⁇ NMR (D2O/DSS) d 7.6-7.3 (m, 4 ⁇ ), 6.64 (s, IH), 5.58

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention se rapporte à un procédé pour traiter les infections virales à l'aide de composés antiviraux d'indolizino[1,2-b]quinolinone substitués, et des compositions pharmaceutiques de ceux-ci.
EP93912281A 1992-04-17 1993-04-15 INDOLIZINO 1,2-b]QUINOLINONES SUBSTITUEES. Withdrawn EP0637960A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87064992A 1992-04-17 1992-04-17
US870649 1992-04-17
PCT/US1993/003596 WO1993020818A1 (fr) 1990-10-31 1993-04-15 INDOLIZINO[1,2-b]QUINOLINONES SUBSTITUEES

Publications (2)

Publication Number Publication Date
EP0637960A1 true EP0637960A1 (fr) 1995-02-15
EP0637960A4 EP0637960A4 (fr) 1995-06-07

Family

ID=25355849

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93912281A Withdrawn EP0637960A4 (fr) 1992-04-17 1993-04-15 INDOLIZINO 1,2-b]QUINOLINONES SUBSTITUEES.

Country Status (8)

Country Link
EP (1) EP0637960A4 (fr)
JP (1) JPH07506099A (fr)
KR (1) KR950701219A (fr)
CN (1) CN1083064A (fr)
AU (1) AU4288893A (fr)
CA (1) CA2118324A1 (fr)
TW (1) TW264471B (fr)
ZA (1) ZA932721B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102093358B (zh) * 2011-02-21 2012-09-05 中山大学 溴代中氮茚并喹啉二酮类衍生物及其在制备抗菌药物中的应用
CN104398514B (zh) * 2014-10-28 2017-04-19 中山大学 氯喹在制备抗疱疹病毒药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016904A1 (fr) * 1990-05-08 1991-11-14 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Procede utile pour traiter des infections retrovirales chez des mammiferes
WO1992006095A1 (fr) * 1990-09-28 1992-04-16 Smithkline Beecham Corporation Procede de preparation de certains pyrano[3', 4':6,7]-indolizino[1,2-b]quinolinones
WO1992007856A1 (fr) * 1990-10-31 1992-05-14 Smithkline Beecham Corporation INDOLIZINO[1,2-b]QUINOLINONES SUBSTITUEES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016904A1 (fr) * 1990-05-08 1991-11-14 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Procede utile pour traiter des infections retrovirales chez des mammiferes
WO1992006095A1 (fr) * 1990-09-28 1992-04-16 Smithkline Beecham Corporation Procede de preparation de certains pyrano[3', 4':6,7]-indolizino[1,2-b]quinolinones
WO1992007856A1 (fr) * 1990-10-31 1992-05-14 Smithkline Beecham Corporation INDOLIZINO[1,2-b]QUINOLINONES SUBSTITUEES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9320818A1 *

Also Published As

Publication number Publication date
CA2118324A1 (fr) 1993-10-28
TW264471B (fr) 1995-12-01
EP0637960A4 (fr) 1995-06-07
JPH07506099A (ja) 1995-07-06
KR950701219A (ko) 1995-03-23
AU4288893A (en) 1993-11-18
ZA932721B (en) 1993-11-29
CN1083064A (zh) 1994-03-02

Similar Documents

Publication Publication Date Title
FI76087C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 9-(2-hydroxietoximetyl)guaninderivat.
JP2578576B2 (ja) キノベンゾオキサジン，キノベンゾチアジン及びピリドーアクリジン抗腫瘍薬
JPH0633268B2 (ja) 水溶性カンプトテシン類似体
CN101675054A (zh) 环杷明内酰胺类似物及其使用方法
BG65195B1 (bg) Тетрахидропиридоетери
AU716656B2 (en) Selected derivatives of K-252a
AU8940491A (en) Substituted indolizino(1,2-b)quinolinones
KR100823762B1 (ko) 알킬화된 이미다조피리딘 유도체
JPH08503221A (ja) 水溶性カンプトテシン誘導体
DE69508421T2 (de) SPIRO[HETEROZYCLISCHE-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN]-4'-ONE, IHRE HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL
JP2002528548A (ja) イミダゾナフチリジン
WO1993016698A1 (fr) FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES SUBSTITUEES
US5883255A (en) Substituted indolizino 1,2-b!quinolinones
KR100762556B1 (ko) 토포이소머라제 Ⅰ 억제작용이 있는 캄프토테신 β-알라닌에스테르
KR20020084082A (ko) 토포이소머라제 ⅰ 억제작용이 있는10,11-디플루오로메틸렌디옥시캄프토테신 화합물
WO1993020818A1 (fr) INDOLIZINO[1,2-b]QUINOLINONES SUBSTITUEES
EP0637960A1 (fr) INDOLIZINO 1,2-b]QUINOLINONES SUBSTITUEES
EP0130126A1 (fr) (S)-(Dihydroxy-2,3 propoxy-1 méthyl)-9 guanine et ses dérivés acylés, leur préparation et leur application comme agents antiherpétiques
CN110903289B (zh) 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途
US6642248B2 (en) Benzo[b]pyrano[3,2-h]acridin-7-one compounds
AU642738B2 (en) Novel cyclobutane derivatives
EP0445813B1 (fr) 7-(Diphénylméthyl)oxy-9a-méthoxymitosane, sa préparation et son utilisation
WO1995003803A1 (fr) FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES SUBSTITUEES
AU684777B2 (en) Substituted methylenedioxy(3',4':6,7)indolizino-(1,2-b)quinolinones
US20040180917A1 (en) Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C07D471/14

17Q First examination report despatched

Effective date: 19980330

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981010

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012264

Country of ref document: HK

RTI1 Title (correction)

Free format text: SUBSTITUTED INDOLIZINO 1,2-B QUINOLINONES